Poison Or Antibiotic? a Guide to "Class" Entries

Total Page:16

File Type:pdf, Size:1020Kb

Poison Or Antibiotic? a Guide to Poison or Antibiotic? A Guide to “Class” Entries Preface Most entries in the Poisons List and the First, Second and Third Schedules to the Pharmacy and Poisons Regulations are in the form of individual drugs and their salts, e.g. “Abacavir; its salts”. However, some entries are in the form of a “class”, e.g. “Barbituric acid; its salts; its derivatives …”. In such cases, it is not always clear which drugs are members of the class (e.g. amobarbital, barbital, pentobarbital, phenobarbital, etc. are poisons, being derivatives of barbituric acid). Likewise, the Antibiotics Ordinance applies to the substances specified in Schedule 1 to the Antibiotics Regulations, to their salts and derivatives, and to the salts of such derivatives. Again, it is not always clear which drugs are derivatives of an antibiotic named in the Schedule (e.g. demeclocycline, doxycycline, tigecycline, etc. are antibiotics, being derivatives of “Tetracycline” named in the Schedule). This Guide provides a list of such drugs which are available as registered pharmaceutical products in Hong Kong. Drugs which are not available as registered pharmaceutical products in Hong Kong are also included in this Guide as far as possible. It should be noted that it is not possible to compile a complete list of all these drugs, simply because there is no limit to the number of “derivatives” a parent chemical can have. This Guide should be read in conjunction with the Poisons List, the First, Second and Third Schedules to the Pharmacy and Poisons Regulations, and Schedule 1 to the Antibiotics Regulations, if the poison/antibiotic classification of a particular pharmaceutical product is to be determined. Pharmaceutical Service Department of Health September 2007 Step-by-step guidance on determining the poison/antibiotic classification of a pharmaceutical product 1. Identify the (first) drug contained in the pharmaceutical product. 2. If this drug is found in the Poisons List, continue to look for it in the First and Third Schedules to the Pharmacy and Poisons Regulations to determine the “poison” classification of the pharmaceutical product containing this drug. Then look for it in the Second Schedule to determine if the product is exempted from control as poison under that Schedule. 3. If the drug is not found in the Poisons List, look for it in Schedule 1 to the Antibiotics Regulations. 4. If the drug is found in Schedule 1, the pharmaceutical product will be an antibiotic. 5. If the drug is found neither in the Poisons List nor in Schedule 1 to the Antibiotics Regulations, look for it in the Index to the Guide. 6. If the drug is found in the Index to the Guide, note the Item Number against it, then turn to the Guide itself to identify the Item number and the corresponding Entry in the Poisons List or Antibiotics Schedule of the drug. 7. Repeat steps 2 to 5 with respect to this entry, to determine the classification of the pharmaceutical product containing this drug. 8. If the drug is not found in the Index to the Guide, look for its synonyms (in “Martindale”, the Merck Index, etc), and repeat steps 2 to 7 with respect to each synonym. 9. If none of the synonyms is found in the Index to the Guide after repeating steps 2 to 7, the pharmaceutical product containing the drug will be neither a poison nor an antibiotic. 10. For a multi-component product, repeat the above steps with respect to each component. The “poison” classification of the product itself will be that of the most stringently classified component. In addition, if one component is classified as antibiotic, the product itself will also be classified as an antibiotic. Index to the Guide Drug Name Item Amoxicillin 105 No. Ampicillin 105 Acepromazine 108 Amylobarbitone 36 Acetarsol 33 Amylocaine 24 Acetophenazine 108 Androstenediol 29 Acetoxypregnenolone 126 Androstenedione 29 Acetyl sulfamethoxypyrazine 25 Antihaemophilic factor 41 Acetyldigitoxin 63 Antimony potassium tartrate 32 Acetyldigoxin 63 Antimony sodium gluconate 32 Acetyldihydrocodeinone 65 Aprobarbital 36 Acetylkitasamycin 48 Arbekacin 87 Aconitine 5 Arbutamine 126 Adefovir dipivoxil 2 Arsanilic acid 33 Adiphenine 24 Arsenamide 33 Adrenaline 126 Arsenic Trioxide 33 Ajmaline 19 Arsthinol 33 Alatrofloxacin 131 L-Asparaginase 58 Alclofenac monoethanolamine 4 Atropine methobromide 6 Alclometasone 126 Atropine methonitrate 6 Aldosterone 126 Azaribine 34 Algestone 126 Azatadine 31 Algestone acetophenide 29 Azathioprine 90 Allobarbital 36 Azidamphenicol 51 Allyloestrenol 29 Azithromycin 69 Alphadolone acetate 23 Azosemide 55 Alprazolam 61 Aztreonam 105 Althiazide 53 Bacampicillin 105 Altrenogest 29 Bamipine 31 Altretamine 77 Barbital 36 Ambucaine 24 Barbitone 36 Amcinonide 126 Beclomethasone 126 Amethocaine 24 Bekanamycin 87 Amfepramone 96 Bendamustine 99 Amikacin 87 Bendrofluazide 53 Aminosalicylate 28 Bendroflumethiazide 53 p-Aminosalicylic acid hydrazide 28 Benfluorex 96 Amitriptylinoxide 119 Benmoxine 78 Amobarbital 36 Benoxinate 24 Amodiaquin 52 Benperidol 76 Benzathine Benzylpenicillin 105 Carbarsone 33 Benzestrol 29 Carbenicillin 105 Benzocaine 26 Carbetocin 104 Benzodepa 35 Carbinoxamine 31 Benzoylpas 28 Carbocloral 50 Benzphetamine 96 Carboprost 118 Benzthiazide 53 Carboquone 35 Benzylhydrochlorothiazide 53 Carfecillin 105 Benzylpenicillin 105 Cargutocin 104 Benzylsulfamide 25 Carindacillin 105 Bepotastine 31 Carmofur 71 Betamethasone 126 Carphenazine 108 Boldenone 29 Cathine 11 Brallobarbital 36 Cefaclor 49 Bromazepam 61 Cefadroxil 49 Bromperidol 76 Cefalexin 49 Brompheniramine 31 Cefaloridine 49 Bromvalerylurea 42 Cefalotin 49 Broparestrol 29 Cefamandole 49 Budesonide 126 Cefapirin 49 Bufotenine 81 Cefatrizine 49 Butabarbital 36 Cefazedone 49 Butacaine 26 Cefcapene 49 Butalbital 36 Cefdinir 49 Butamben 26 Cefditoren 49 Butaperazine 108 Cefepime 49 Butethamate 24 Cefetamet 49 Butethamine 26 Cefixime 49 Buthiazide 53 Cefmenoxime 49 Butobarbital 36 Cefminox 49 Butoxycaine 24 Cefodizime 49 Butriptyline 119 Cefonicid 49 Butropium 15 Cefoperazone 49 Butyl aminobenzoate 26 Ceforanide 49 Cacodylate 33 Cefoselis 49 Cafedrine 96 Cefotaxime 49 Calcitonin 129 Cefotiam 49 Camazepam 61 Cefpimizole 49 Candesartan cilexetil 45 Cefpiramide 49 Canfosfamide 99 Cefpirome 49 Cannabidiol 47 Cefpodoxime 49 Cefprozil 49 Clopenthixol 54 Cefradine 49 Cloprednol 126 Cefroxadine 49 Cloprostenol 118 Cefsulodin 49 Clorazepate 61 Ceftazidime 49 Clostebol 29 Ceftibuten 49 Cloxacillin 105 Ceftiofur 49 Cloxazolam 61 Ceftizoxime 49 Cloxotestosterone 29 Ceftriaxone 49 Clozapine 61 Chloral betaine 50 Cocaethylene 10 Chloral hydrate 50 Codoxime 64 Alpha-Chloralose 50 Colchicine 8 Chlorambucil 99 Colistimethate sodium 59 Chloraminophenamide 55 Colpormon 29 Chlormadinone acetate 29 Combelen 108 Chlornaphazine 99 Cortisone 126 Chloroprednisone 126 Cortivazol 126 Chloroprocaine 24 Crotarbital 36 Chloropyramine 30 Cyacetacide 79 Chlorothen 30 Cyamemazine 108 Chlorotrianisene 29 Cyclobarbital 36 Chlorphenamide 55 Cyclodrine 24 Chlorpheniramine 31 Cyclomethycaine 24 Chlorpromazine 108 Cyclopenthiazide 53 Choline theophyllinate 128 Cyclopentobarbital 36 Ciclesonide 126 Cyclopentolate 24 Cimetropium bromide 14 Cyclophosphamide 99 Cinchocaine 80 Cyclothiazide 53 Cinchophen 110 Cymarin 124 Cinnarizine 31 Cyproheptadine 31 Clarithromycin 69 Cyproterone 29 Clemastine 31 Dalfopristin 115 Clemizole 31 Danazol 29 Clindamycin 88 Deanol Benzilate 24 Clobetasol 126 Decamethonium bromide 114 Clobetasone 126 Deflazacort 126 Clocapramine 57 Defosfamide 99 Clocinizine 31 Delorazepam 61 Clocortolone 126 Demeclocycline 127 Clonazepam 61 Demegestone 29 Clopamide 55 Demoxytocin 104 Denopterin 27 Dimethylaminoethyl 19 Deoxycorticosterone 126 Reserpilinate Deprenyl 96 Dimethylthiambutene 68 Deptropine 31 Dimetindene 31 Deserpidine 19 Dimetofrine 126 Deslanoside 63 Diphenylpyraline 31 Desmopressin 135 Dipivefrin 126 Desogestrel 29 Dipyrone 101 Desonide 126 Dirithromycin 69 Desoxymethasone 126 Divalproex sodium 133 Dexamethasone 126 Dixyrazine 108 Dexbrompheniramine 31 Doxifluridine 71 Dexchlorpheniramine 31 Doxorubicin 3 Dextromethorphan 92 Doxycycline 127 Dextropropoxyphene 116 Drosprienone 29 Dextrorphan 82 Drostanolone 29 Diacetyldihydromorphine 66 Dydrogesterone 29 Diacetylmorphine 17 Eburnamonine 21 Diaziquone 35 Elcatonin 129 Dibekacin 87 Embramine 31 Dichloralphenazone 50 Emedastine 31 Dichlorisone 126 Enprostil 118 Dichlorphenamide 55 Ephedrine 11 Dicloxacillin 105 Epicillin 105 Dienoestrol 29 Epimestrol 29 Dienogest 29 Epinastine 31 Diethylpropion 96 Epinephrine 126 Diethylstilbestrol 29 Epirubicin 3 Diethylthiambutene 68 Epitiostanol 29 Diflorasone 126 Epoetin alfa 120 Diflucortolone 126 Eptacog alfa (activated) 41 Difluprednate 126 Equilin 29 Digitalin 63 Ergocornine 12 Digitoxin 63 Ergocristine 12 Digoxin 63 Ergocryptine 12 Dihydrostreptomycin 123 Ergometrine 12 Diisopropanolamine felbinac 38 Ergotamine 12 Dimenhydrinate 30 Ergotoxine 12 Dimethisterone 29 Ertapenem 105 Dimethocaine 26 Escitalopram 56 Eseridine salicylate 7 Estazolam 61 Flunitrazepam 61 Estradiol 29 Fluocortin butyl 126 Estramustine 99 Fluocortolone 126 Estrapronicate 29 Fluorometholone 126 Estriol 29 Fluoxymesterone 29 Estrone 29 Fluperolone acetate 126 Estropipate 29 Fluphenazine 108 Ethinyloestradiol 29 Fluprednidene acetate 126 Ethisterone 29 Fluprednisolone 126 Ethotoin 111 Flurandrenolide 126 Ethybenztropine 37 Flurazepam 61 Ethyl loflazepate 61 Flurogestone acetate 29 Ethylamphetamine 96 Fluticasone 126 Ethylmethylthiambutene 68 Flutoprazepam 61 Ethyloestrenol 29 Fluzacort 126 Ethynodiol 29 Follicle-stimulating hormone 112
Recommended publications
  • (12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten Et Al
    US00787 1995 B2 (12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten et al. (45) Date of Patent: *Jan. 18, 2011 (54) DRUG DELIVERY SYSTEM COMPRISINGA (52) U.S. Cl. ....................................... 514/171; 514/182 TETRAHYDROXYLATED ESTROGEN FOR (58) Field of Classification Search ................. 514/171, USE IN HORMONAL CONTRACEPTION 514f182 See application file for complete search history. (75) Inventors: Evert Johannes Bunschoten, Heesch (NL); Herman Jan Tijmen Coelingh (56) References Cited Bennink, Driebergen (NL); Christian U.S. PATENT DOCUMENTS Franz Holinka, New York, NY (US) 3,440,320 A 4, 1969 Sackler et al. O O 3,797.494. A 3, 1974 Zaffaroni (73) Assignee: Pantarhei Bioscience B.V., Al Zeist 4,460.372 A 7/1984 Campbell et al. (NL) 4,573.996 A 3/1986 Kwiatek et al. 4,624,665 A 1 1/1986 Nuwayser (*) Notice: Subject to any disclaimer, the term of this 4,722,941 A 2f1988 Eckert et al. patent is extended or adjusted under 35 4,762,717 A 8/1988 Crowley, Jr. U.S.C. 154(b) by 1233 days. 4.937,238 A 6, 1990 Lemon 5,063,507 A 1 1/1991 Lindsey et al. This patent is Subject to a terminal dis- 5,130,137 A 7/1992 Crowley, Jr. claimer. 5,211,952 A 5/1993 Spicer et al. 5,223,261 A 6/1993 Nelson et al. 5,340,584 A 8/1994 Spicer et al. (21) Appl. No.: 10/478,357 5,340,585 A 8/1994 Pike et al. 1-1. 5,340,586 A 8, 1994 Pike et al.
    [Show full text]
  • New Rules Pertaining to the Banning of Anabolic Steroids in the Western Australian Harness Racing Industry to Be Introduced 1St September 2014
    NEW RULES PERTAINING TO THE BANNING OF ANABOLIC STEROIDS IN THE WESTERN AUSTRALIAN HARNESS RACING INDUSTRY TO BE INTRODUCED 1ST SEPTEMBER 2014 Notice is hereby given that the Board of Racing and Wagering WA have resolved that the RWWA Rules of Harness Racing 2004 be amended. In accordance with section 45 (1) (b) of the Racing and Wagering Western Australia Act 2003 the Board of Racing and Wagering WA on the 10th April 2014 resolved that these amendments be adopted accordingly into the RWWA Rules of Harness Racing. The Harness Racing Board had advised of these amendments and the RWWA Board has determined that these amendments will come into effect on 1st September 2014. The details of the relevant rules pertaining to this ban of anabolic steroids for reference can be found following this advice. There are many implications arising from the introduction of these rules, and to assist trainers and veterinarians to comply with the new rules the following explanatory statement has been prepared. Which steroids are banned under these rules? The new rules ban the use of "anabolic androgenic steroids" in Standardbred horses at any time from birth until retirement. "Anabolic androgenic steroids" include those that are currently registered in Australia by the APVMA for use in horses, such as boldenone, ethylestrenol (in Nitrotain), methandriol, nandrolone, stanozolol and testosterone. Exogenous anabolic androgenic steroids that are banned also include but are not limited to those listed in the WADA prohibited list, such as 1-androstenediol; 1-androstenedione;
    [Show full text]
  • Risk of Breast Cancer After Stopping Menopausal Hormone Therapy In
    Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort Agnès Fournier, Sylvie Mesrine, Laure Dossus, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Nathalie Chabbert-Buffet To cite this version: Agnès Fournier, Sylvie Mesrine, Laure Dossus, Marie-Christine Boutron-Ruault, Françoise Clavel- Chapelon, et al.. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment, Springer Verlag, 2014, 145 (2), pp.535-43. 10.1007/s10549- 014-2934-6. inserm-01319982 HAL Id: inserm-01319982 https://www.hal.inserm.fr/inserm-01319982 Submitted on 23 May 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. TITLE PAGE Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort Authors : Agnès Fournier1,2,3, Sylvie Mesrine1,2,3, Laure Dossus1,2,3, Marie-Christine Boutron- Ruault1,2,3, Françoise Clavel-Chapelon1,2,3, Nathalie Chabbert-Buffet4 Affiliations: 1. Inserm, Center for research in Epidemiology and Population Health, U1018, Nutrition, Hormones and Women’s Health team, F-94807, Villejuif, France 2. Univ Paris-Sud, UMRS 1018, F-94807, Villejuif, France 3. Institut Gustave Roussy, F-94805, Villejuif, France 4.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • MICROCOMP Output File
    108TH CONGRESS 2D SESSION S. 2195 AN ACT To amend the Controlled Substances Act to clarify the defini- tion of anabolic steroids and to provide for research and education activities relating to steroids and steroid precursors. 1 Be it enacted by the Senate and House of Representa- 2 tives of the United States of America in Congress assembled, 3 SECTION 1. SHORT TITLE. 4 This Act may be cited as the ‘‘Anabolic Steroid Con- 5 trol Act of 2004’’. 2 1 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 2 ACT. 3 (a) DEFINITIONS.—Section 102 of the Controlled 4 Substances Act (21 U.S.C. 802) is amended— 5 (1) in paragraph (41)— 6 (A) by realigning the margin so as to align 7 with paragraph (40); and 8 (B) by striking subparagraph (A) and in- 9 serting the following: 10 ‘‘(A) The term ‘anabolic steroid’ means any drug or 11 hormonal substance, chemically and pharmacologically re- 12 lated to testosterone (other than estrogens, progestins, 13 corticosteroids, and dehydroepiandrosterone), and 14 includes— 15 ‘‘(i) androstanediol— 16 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 17 ‘‘(II) 3α,17β-dihydroxy-5α-androstane; 18 ‘‘(ii) androstanedione (5α-androstan-3,17- 19 dione); 20 ‘‘(iii) androstenediol— 21 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy- 22 5α-androst-1-ene); 23 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy- 24 5α-androst-1-ene); 25 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy- 26 androst-4-ene); and †S 2195 ES 3 1 ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy- 2 androst-5-ene); 3 ‘‘(iv) androstenedione— 4 ‘‘(I) 1-androstenedione ([5α]-androst-1-en- 5 3,17-dione);
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]